CR8087A - DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR Xa - Google Patents

DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR Xa

Info

Publication number
CR8087A
CR8087A CR8087A CR8087A CR8087A CR 8087 A CR8087 A CR 8087A CR 8087 A CR8087 A CR 8087A CR 8087 A CR8087 A CR 8087A CR 8087 A CR8087 A CR 8087A
Authority
CR
Costa Rica
Prior art keywords
factor
compounds
inhibitors
situations
formula
Prior art date
Application number
CR8087A
Other languages
English (en)
Spanish (es)
Inventor
Wagner Michael
Matter Hans
Urmann Matthias
Ritter Kurt
Nazare Marc
Wehner Volkmar
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33040952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CR8087A publication Critical patent/CR8087A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CR8087A 2003-05-19 2005-11-11 DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR Xa CR8087A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011305A EP1479676A1 (en) 2003-05-19 2003-05-19 Benzimidazole-derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
CR8087A true CR8087A (es) 2006-09-22

Family

ID=33040952

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8087A CR8087A (es) 2003-05-19 2005-11-11 DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR Xa

Country Status (29)

Country Link
EP (2) EP1479676A1 (enExample)
JP (1) JP4658940B2 (enExample)
KR (1) KR20060014056A (enExample)
CN (2) CN100484935C (enExample)
AR (1) AR045683A1 (enExample)
AT (1) ATE474838T1 (enExample)
AU (1) AU2004238497B2 (enExample)
BR (1) BRPI0410446A (enExample)
CA (1) CA2526065A1 (enExample)
CL (1) CL2004001078A1 (enExample)
CR (1) CR8087A (enExample)
DE (1) DE602004028240D1 (enExample)
EC (1) ECSP056178A (enExample)
MA (1) MA27798A1 (enExample)
MX (1) MXPA05012231A (enExample)
NO (1) NO20055910L (enExample)
NZ (1) NZ543670A (enExample)
OA (1) OA13168A (enExample)
PA (1) PA8603501A1 (enExample)
PE (1) PE20050198A1 (enExample)
RS (1) RS20050856A (enExample)
RU (1) RU2346944C2 (enExample)
SA (1) SA04250196B1 (enExample)
TN (1) TNSN05297A1 (enExample)
TW (1) TW200503696A (enExample)
UA (1) UA82100C2 (enExample)
UY (1) UY28324A1 (enExample)
WO (1) WO2004101553A1 (enExample)
ZA (1) ZA200508151B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10342570A1 (de) * 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
WO2008033739A2 (en) * 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
DE102010018299A1 (de) 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
JP6535007B2 (ja) * 2013-12-20 2019-06-26 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー.エル.エー.チャイナ 新規ピペリジンカルボキサミド化合物、その調製方法及び使用
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
AU2019223182B2 (en) 2018-02-26 2021-08-19 Gilead Sciences, Inc. Substituted pyrrolizine compounds as HBV replication inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1377642A (en) * 1971-01-14 1974-12-18 Koninklijke Gist Spiritus Penicillanic and cephalosporanic acid derivatives
US4269846A (en) * 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4897401A (en) * 1987-06-19 1990-01-30 Janssen Pharmaceutical N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases
DE3828537A1 (de) * 1988-08-23 1990-03-01 Basf Ag Neue n-substituierte benzimidazol-2-carbonsaeureanilide, deren verwendung als lichtschutzmittel, insbesondere polymere und diese anilide enthaltendes organisches material
JPH0324609A (ja) * 1989-06-21 1991-02-01 Mitsuba Electric Mfg Co Ltd I/o用バッファic
JPH03184043A (ja) * 1989-12-14 1991-08-12 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
KR100190299B1 (ko) * 1990-07-19 1999-06-01 디르크 반테 신규한 옥사졸릴 유도체
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CA2200959C (en) * 1994-09-30 2000-05-23 Kishor A. Desai 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives
JPH08208640A (ja) * 1995-02-06 1996-08-13 Nisshin Flour Milling Co Ltd ベンズイミダゾール誘導体およびそれを含有する心不全治療薬
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
JPH09124609A (ja) * 1995-11-07 1997-05-13 Nissan Chem Ind Ltd ベンズイミダゾール誘導体
JPH10182459A (ja) * 1996-12-26 1998-07-07 Otsuka Pharmaceut Co Ltd cGMP分解酵素阻害剤
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
DE69919149D1 (de) * 1998-04-10 2004-09-09 Japan Tobacco Inc Amidin-verbindungen
BR0314059A (pt) * 2002-09-06 2005-07-05 Janssen Pharmaceutica Nv Compostos heterocìclicos

Also Published As

Publication number Publication date
WO2004101553A1 (en) 2004-11-25
EP1636216A1 (en) 2006-03-22
KR20060014056A (ko) 2006-02-14
DE602004028240D1 (de) 2010-09-02
TNSN05297A1 (en) 2007-07-10
MA27798A1 (fr) 2006-03-01
EP1636216B1 (en) 2010-07-21
MXPA05012231A (es) 2006-08-18
TW200503696A (en) 2005-02-01
ZA200508151B (en) 2007-02-28
RU2346944C2 (ru) 2009-02-20
PA8603501A1 (es) 2004-11-26
HK1089174A1 (zh) 2006-11-24
AU2004238497A1 (en) 2004-11-25
UY28324A1 (es) 2004-12-31
OA13168A (en) 2006-12-13
JP2006528213A (ja) 2006-12-14
AR045683A1 (es) 2005-11-09
NO20055910L (no) 2006-02-10
PE20050198A1 (es) 2005-04-25
EP1479676A1 (en) 2004-11-24
ECSP056178A (es) 2006-08-30
RS20050856A (sr) 2007-11-15
BRPI0410446A (pt) 2006-06-06
ATE474838T1 (de) 2010-08-15
AU2004238497B2 (en) 2010-07-22
CA2526065A1 (en) 2004-11-25
RU2005139555A (ru) 2006-06-10
WO2004101553B1 (en) 2005-03-03
UA82100C2 (uk) 2008-03-11
CL2004001078A1 (es) 2005-04-08
CN100484935C (zh) 2009-05-06
NZ543670A (en) 2008-09-26
CN101139346A (zh) 2008-03-12
JP4658940B2 (ja) 2011-03-23
SA04250196B1 (ar) 2008-11-18
CN1791598A (zh) 2006-06-21

Similar Documents

Publication Publication Date Title
UY28778A1 (es) Derivados de pirrol como inhibidores del factor xa
UY28325A1 (es) Nuevos derivados de indol como inhibidores del factor xa
CR20240038A (es) Inhibidores del inflamasoma nlrp3
EA201001523A1 (ru) Ингибиторы матриксной металлопротеазы на основе арилсульфонамида
TW200510400A (en) Indazole-derivatives as factor Xa inhibitors
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
HN2001000019A (es) Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4.
NO20084502L (no) Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
ATE331711T1 (de) Entzündungshemmende 3-arylthio-3- thiazolylalkylamine
MX2025010920A (es) Compuestos quimicos
CR8087A (es) DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR Xa
PA8816101A1 (es) Clorotiofeno - amidas como inhibidores de los factores de coagulacion xa y trombina
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
AR026257A1 (es) N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen
CR8088A (es) DERIVADOS DE AZAINDOL COMO INHIBIDORES DEL FACTOR Xa
PE20050154A1 (es) DERIVADOS DE TRIAZOL COMO INHIBIDORES DEL FACTOR Xa
ATE394414T1 (de) Hemmstoffe des gerinnungsfaktors xa, ihre herstellung und verwendung
NO20044321L (no) Piperazinyl- eller piperidinylamin-sulfaminsyreamider som inhibitorer av steroid sulfatase
MY148565A (en) Agent for therapy and/or improvement of disseminated intravascular coagulation
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-
NO20055517L (no) 4-,6-O 7-hydroksyindoler med N-oksidgrupper og anvendelse av disse som terapeutiske midler
EP4119165A4 (en) NOVEL 3,5-DIAMINOBENZOIC ACID COMPOUND, AND PIN1 INHIBITOR AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES USING SAME

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)